Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

The findings can help guide ongoing and future clinical trials to help solve remaining challenges in LS-SCLC. | Image credit: Jennifer - stock.adobe
Neoadjuvant Immunotherapy Plus Chemotherapy Shows Promise in LS-SCLC

August 31st 2025

The findings may inform future studies on the therapeutic strategy for patients with small cell lung cancer (SCLC).

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

cancer vaccine | Image credit: IO Biotech
From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

May 3rd 2025

More News

what we're reading logo
April 19th 2024

What We’re Reading: Health Care Antitrust Portal; CAR T Label Updates; Weight-Loss Shots and Fertility

AJMC Staff
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Columvi packaging | Image: Genentech
April 15th 2024

STARGLO: Glofitamab Plus Chemo Meets Primary OS End Point in R/R DLBCL in Phase 3 Study

AJMC Staff
Results show the bispecific antibody is effective in an earlier line of treatment.
AJMC EBO logo | Image credit : AJMC
April 15th 2024

Health Care Practitioners Push for Legislative Solution to Prevent Chemotherapy Shortage “Groundhog Day”

Ryan Flinn
Fred Locke, MD | Image credit: Moffitt Cancer Center
April 3rd 2024

How Does Metabolic Tumor Volume Affect Responses to Axi-Cel in LBCL?

Mary Caffrey
The authors say a standard method of assessing metabolic tumor volume would be needed for its use to become widespread.
FCS logo | Image credit: FCS
April 2nd 2024

Florida Cancer Specialists & Research Institute Forms Analytics Subsidiary

AJMC Staff
Opdivo and Yervoy | Image credit: Bristol Myers Squibb
March 30th 2024

Review: Neoadjuvant Dual ICIs Offer Better Response Than Anti-PD1 Monotherapy in High-Risk Resectable Melanoma

Mary Caffrey
An alternative dose of ipilimumab and nivolumab had less toxicity than a conventional dose, the results show.
Man receiving infusion | Image credit: National Cancer Institute
March 28th 2024

Immunotherapy Before Noon Linked to Improved Survival in mRCC

Mary Caffrey
Results are consistent with the authors' prior findings on the possible effects of circadian rhythm on outcomes after immunotherapy.
Princess Catherine, Duchess of Wales | Image credit: Wikipedia
March 23rd 2024

Preventative Chemotherapy? Not Quite, but Studies Are Underway in Immunoprevention

Mary Caffrey
The Princess of Wales is likely referencing adjuvant chemotherapy, but there is a growing field of immunoprevention, which seeks to target precancerous lesions or block heritable cancers.
Keytruda packaging | Image credit: Merck
March 21st 2024

Pembrolizumab Plus Olaparib Falls Short in Phase 3 Study When Used First Line in Metastatic, Nonsquamous NSCLC

Mary Caffrey
This is the second time the combination has failed to meet end points in a trial in non–small cell lung cancer (NSCLC).
FDA Grants Accelerated Approval to Liso-Cel for CLL/SLL After BTK, BCL-2 Inhibitors
March 15th 2024

FDA Grants Accelerated Approval to Liso-Cel for CLL/SLL After BTK, BCL-2 Inhibitors

Mary Caffrey
The approval fills a void for patients with CLL or SLL whose disease progresses after treatment with a BTK inhibitor and a BCL-2 inhibitor; until now, there has been no standard of care.
Registry Data Inconclusive on Risk of Secondary Primary Malignancy After CAR T, Authors Say
March 14th 2024

Registry Data Inconclusive on Risk of Secondary Primary Malignancy After CAR T, Authors Say

Mary Caffrey
Results come amid the FDA's review of chimeric antigen receptor (CAR) T-cell therapy.
researcher in lab | Image credit: StockPhotoPro - stock.adobe.com
March 8th 2024

Real-World Study Confirms Nivolumab Plus Ipilimumab Safety in Advanced NSCLC

Skylar Jeremias
A real-world study confirmed that the rate of adverse events associated with first-line nivolumab plus iplimumab therapy was in line with the safety profiles of other immuno-oncology and chemotherapy combination regimens.
Clinician touching a graphic saying FDA Approved | image credit: wladimir1804 - stock.adobe.com
March 7th 2024

Frontline Nivolumab Plus Chemotherapy Approved for Unresectable or Metastatic Urothelial Carcinoma

Laura Joszt, MA
The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population.
Top 5 Immuno-Oncology Articles of 2023
December 26th 2023

Top 5 Most-Read Immuno-Oncology Articles of 2023

Rose McNulty
Multiple myeloma blood testing - luchschenF - stock.adobe.com
December 24th 2023

ASH Abstracts Show PRO Improvements, Long-Term Efficacy of Cilta-Cel in MM

Rose McNulty
Data presented at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition highlighted improvements in patient-reported outcomes (PROs) with ciltacabtagene autoleucel (cilta-cel) in multiple myeloma (MM).
Top 5 Evidence-Based Oncology articles of 2023
December 22nd 2023

Top 5 Most-Read Evidence-Based Oncology™ Articles in 2023

Mary Caffrey
Articles highlighting links between COVID-19 and cancer were among the most-read in Evidence-Based Oncology™ in 2023.
FDA Approved | Image credit: chrisdorney - stock.adobe.com
December 18th 2023

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Bladder Cancer

Rose McNulty
In the phase 3 EV-302/KEYNOTE-A39 clinical trial, the antibody-drug conjugate enfortumab vedotin plus PD-1 inhibitor pembrolizumab nearly doubled both median overall survival and progression-free survival compared with chemotherapy.
Highlights From the 2023 ESMO Congress
December 15th 2023

ICYMI: Highlights From ESMO Congress 2023

Rose McNulty
Our most-read coverage from the 2023 European Society for Medical Oncology (ESMO) Congress included potentially practice-changing findings across a range of cancer types, including lung cancer, breast cancer, and urothelial carcinoma.
CAR T cell AI-generated image | Image credit: AIGen - stock.adobe.comCAR T cell AI-generated image | Image credit: AIGen - stock.adobe.com
December 11th 2023

Second-Line Axi-Cel Prolongs Survival Over Standard of Care in Elderly Patients With R/R LBCL

Rina Lokaj
The administration of axicabtagene ciloleucel in the second-line setting improved overall survival and progression-free survival vs standard-of-care treatment in patients with relapsed/refractory large B-cell lymphoma who are at least 65 years of age.
Urothelial carcinoma | Image credit: Matthieu - stock.adobe.com
November 30th 2023

Dr Guru Sonpavde: Nivolumab Plus Gemcitabine-Cisplatin Holds Promise in Urothelial Cancer

Rose McNulty
Urothelial carcinoma has long been treated with chemotherapy as the frontline standard of care, but recent trial results in the space have potential to add to the treatment armamentarium and improve outcomes for the first time in decades.
Immune checkpoint inhibition | Image credit: Masaki - stock.adobe.com
November 25th 2023

Moving Beyond Steroids to Treat Immunotherapy Toxicity

Laura Joszt, MA
Managing toxicities for patients on immunotherapy requires collaboration with specialists to manage specific organ toxicities and moving beyond steroids, according to a presentation at the ESMO Congress 2023.
FDA Approved | Image credit: chrisdorney - stock.adobe.com
November 16th 2023

FDA Approves First-Line Pembrolizumab Plus Chemotherapy for Unresectable HER2–, Gastric/GEJ Adenocarcinoma

Chris Ryan
The FDA has approved pembrolizumab (Keytruda) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
FDA on Paper Texture | Image credit: Araki Illustrations - stock.adobe.com
November 9th 2023

FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma

Russ Conroy
Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.
FDA Approved | Image credit: chrisdorney - stock.adobe.com.jpg
November 1st 2023

FDA Approves Pembrolizumab Plus Gemcitabine, Cisplatin for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Rose McNulty
The approval, which is based on results from the phase 3 KEYNOTE-966 trial, marks the sixth indication for pembrolizumab in gastrointestinal cancer.
Endometrial tumor | Image credit: Crystal light - stock.adobe.com
November 1st 2023

Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer

Kristie L. Kahl
The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.
IVBM logo | Image credit: AJMC
October 27th 2023

Novel Therapies Have Significantly Improved Melanoma Outcomes, With More Exciting Options to Come

Laura Joszt, MA
Coverage from the Institute for Value-Based Medicine session with Minnesota Oncology.
COA logo | Image credit: COA
October 26th 2023

Payer Testing Delays Can Lead to Patients Taking Wrong Therapy, Panelists Say

Mary Caffrey
The discussion, "Understanding Biomarkers and the Role They Play in Oncology," came during the Community Oncology Alliance Payer Exchange Summit, held October 23-24 in Reston, Virginia.
EBO logo
October 20th 2023

Navigating Decision-Making When Treating Lymphoma With Bispecific Antibodies vs CAR T-Cell Therapy

Ryan Flinn
Doctor holding a burgundy and white head and neck cancer ribbon | Image credit: Chinnapong - stock.adobe.com
October 12th 2023

Novel Approaches to Head and Neck Cancer at Vanderbilt Ingram Cancer Center

Laura Joszt, MA
Speakers at an Institute for Value-Based Medicine event with Vanderbilt University Medical Center highlighted the novel therapies and techniques being used to improve outcomes for patients with head and neck cancer.
Innovations in Cancer Care Improve Outcomes, but Cost Remains a Barrier: Christine Pfaff, RPh
October 6th 2023

Innovations in Cancer Care Improve Outcomes, but Cost Remains a Barrier: Christine Pfaff, RPh

Maggie L. Shaw Rose McNulty
Christine Pfaff, RPh, senior regional director of operations at American Oncology Network, discusses the role of immunotherapy and precision medicine in oncology, as well as considerations for patient safety and financial toxicity when prescribing oncology drugs.
<12345678
...
15>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo